| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/08923970902817890 |
| P8608 | Fatcat ID | release_22mhgplk5naptbjjtocps3m6wm |
| P698 | PubMed publication ID | 19778176 |
| P2093 | author name string | Mustapha Chamekh | |
| P2860 | cites work | Protein delivery into eukaryotic cells by type III secretion machines | Q28276443 |
| Toll-like receptors in innate immunity | Q28297257 | ||
| The type III secretion injectisome | Q29617944 | ||
| Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group | Q33335409 | ||
| Bacteria as gene delivery vectors for mammalian cells | Q33744891 | ||
| Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group | Q33927770 | ||
| Subversion of a young phagosome: the survival strategies of intracellular pathogens | Q34156277 | ||
| Interleukin-1 receptor antagonist | Q34354989 | ||
| Heterogeneous memory T cells in antiviral immunity and immunopathology | Q34374787 | ||
| Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers | Q34410660 | ||
| Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group | Q34434612 | ||
| Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system | Q34471356 | ||
| Effector and memory CTL differentiation | Q34584974 | ||
| In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. | Q34691545 | ||
| Phagosome maturation: a few bugs in the system. | Q35214412 | ||
| Imbalance of the interleukin 1 system in colonic mucosa--association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2. | Q35841247 | ||
| The immunological challenge to developing a vaccine to the blood stages of malaria parasites. | Q35884247 | ||
| Requirements for Th1-dependent immunity against infection with Leishmania major | Q35893834 | ||
| Biology of adenovirus and its use as a vector for gene therapy | Q35989621 | ||
| Towards safe, non-viral therapeutic gene expression in humans. | Q36068277 | ||
| Shigella spp. and enteroinvasive Escherichia coli pathogenicity factors | Q36267084 | ||
| Use of adenoviral vectors as veterinary vaccines | Q36288927 | ||
| Subversion of cellular functions by Listeria monocytogenes | Q36346114 | ||
| Bacterial gene therapy strategies. | Q36346126 | ||
| Optimization of a type III secretion system-based Pseudomonas aeruginosa live vector for antigen delivery. | Q36452365 | ||
| Intracellular pattern recognition receptors in the host response | Q36528528 | ||
| Viral vector vaccines make memory T cells against malaria. | Q36802741 | ||
| Salmonella type III-mediated heterologous antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors. | Q36919064 | ||
| Attenuated recombinant Yersinia as live oral vaccine carrier to protect against amoebiasis | Q36953936 | ||
| Multiple roles for CD4+ T cells in anti-tumor immune responses | Q37118150 | ||
| The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. | Q37130726 | ||
| Vaccines against intracellular bacterial pathogens | Q37206444 | ||
| Strategies for use of IL-10 or its antagonists in human disease | Q37211255 | ||
| Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid | Q39512148 | ||
| Delivery of biologically active anti-inflammatory cytokines IL-10 and IL-1ra in vivo by the Shigella type III secretion apparatus | Q40005415 | ||
| Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis | Q40640408 | ||
| Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins. | Q41475677 | ||
| Apoptosis as a proinflammatory event: what can we learn from bacteria-induced cell death? | Q41478623 | ||
| CD40-CD40L interaction in immunity against protozoan infections | Q41788290 | ||
| Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium | Q43982547 | ||
| Delivery of epitopes by the Salmonella type III secretion system for vaccine development | Q47793303 | ||
| Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. | Q49073992 | ||
| Prophylactic anti-tumor immunity against a murine fibrosarcoma triggered by the Salmonella type III secretion system | Q50077851 | ||
| Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system | Q50079113 | ||
| Oral somatic transgene vaccination using attenuated S. typhimurium | Q50132575 | ||
| IL-8 is a key chemokine regulating neutrophil recruitment in a new mouse model of Shigella-induced colitis. | Q51189374 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 1-4 | |
| P577 | publication date | 2010-03-01 | |
| P1433 | published in | Immunopharmacology and Immunotoxicology | Q4200316 |
| P1476 | title | Immunomodulation using genetically engineered bacteria for type III-mediated delivery of heterologous antigens and cytokines: potential application in vaccine and therapeutical developments | |
| P478 | volume | 32 |
| Q38034843 | Bacterial vectors for active immunotherapy reach clinical and industrial stages |
| Q36957667 | Engineering the type III secretion system in non-replicating bacterial minicells for antigen delivery |
| Q39251357 | Improving health from the inside: Use of engineered intestinal microorganisms as in situ cytokine delivery system |
| Q38152473 | Live-attenuated bacteria as a cancer vaccine vector |
| Q35025547 | Technologies and approaches to elucidate and model the virulence program of salmonella |
| Q38586932 | Type III secretion systems: the bacterial flagellum and the injectisome |
Search more.